Author Archive Patrick Moreau
One of the best Indonesian casino web site
The internet has created a worldwide betting economy, and with it online betting has exploded. Punters on nearly every corner of the globe can now find an online bookmaker to do their business with. But, which bookmakers should you use to place your bets on? What are the best sports betting websites out there and which ones should you go with?
The Medisun Medical Health Summit was held in Shenzhen
Medisun Regenerative Medical Center and Health Summit
Cancer Vaccine | White House Cancer Lunar Plan | Cancer Proton Beam Treatment
ShenZhen- Hong Kong-GuangZhou
The Medisun Medical Health Summit, co-sponsored by Medisun Regenerative Medical Group, New Life Group and Sunshine Medical Group, was held in Shenzhen, Hong Kong and Guangzhou from September 6 to 9, 2017. The theme of this summit is centered around the prevention and treatment of cancer. The authoritative release of cancer vaccine is the strongest focus of this summit. 
Medisun Medical Group has invited a number of authoritative scientists, medical experts, industry leaders, government agency representatives, business leaders and socialites from the United States, Europe, Japan, Hong Kong and Mainland China to collaborate on cancer prevention worldwide. Leading medical health consultations such as therapeutic technologies, industry regulatory development, and medical platform construction have been fully explored. Nearly 5,000 entrepreneur representatives, medical experts and doctors from the Chinese health industry participated in the listening and sharing. 
Dozens of media interviews and reports at the summit
Madison Cancer Vaccine Launch Ceremony
Chairman Danny Wong said: “The advent of cancer vaccine is the strongest gospel of cancer prevention!”
According to the World Health Organization (WHO), approximately 14 million new cancer cases are diagnosed each year worldwide, and this number is expected to reach 21 million by 2030. As global treatment costs rise, cancer prevention measures are becoming more and more important, which has also made cancer prevention and treatment a high-profile international issue. Medisun’s comprehensive introduction of cancer vaccines is undoubtedly the strongest gospel for cancer prevention. The WT1 gene is a gene representing tumorigenesis in humans, and all human cancers are associated with this genetic mutation. The Nobel Institute of Ecological Medical Sciences has discovered a pathway to inhibit mutations in the WT1 gene, which can be vaccinated to produce memory T cells that inhibit WT1 gene mutations, which are immune to humans.
In addition, Medisun is also committed to the development and clinical use of a variety of other vaccines. Most of the vaccine technology comes from the United States, investing in rapid response to the pandemic virus and cancer control vaccine technology platform, with a market size of more than 2 billion US dollars. The vaccines invested by Medisun can be modularized in Asia and China to produce vaccines that are fully compliant with the United States. Including: Zika virus, Chikungunya fever, Zika/Chikununya heat combination, Ebola virus, human papillomavirus HPV treatment vaccine, head and neck cancer, cervical cancer, cervical lesions, simple Herpesvirus HSV, hepatitis C virus HCV, hepatitis B virus HBV,etc.
Mr. Danny Wong, Chairman of Medici Medical Group, was interviewed by the media about the release of cancer vaccine.
Chairman Danny Wong specifically said: “China’s rapid economic development over the past 20 years has been accompanied by a wave of globalization. China has integrated into the international community in various fields. At the same time, China has introduced high-standard medical technologies and services from Europe, the United States and Japan. It is our mission to make full use of Hong Kong’s advantages as a mature international metropolis and special geographical factors to provide the world’s most advanced medical care to the people of the motherland. 
On-site participants actively asked questions from the cancer vaccine and new cancer treatment technologies to participate in the seminar.
Medisun participates in the White House Cancer Month Plan
Mr. Terry Lierman said: “The greatest progress and breakthrough of mankind is the birth of cancer vaccine!”
Mr. Terry Lierman, a core member of the White House Cancer Month Program, the NIH of the National Institutes of Health, and the founder of the FDA Board of Directors and director of the Meditech Group, said that cancer landing is an amazing cause. It is planned to complete the treatment of 20,000 cancer patients with 60 different technologies worldwide by 2020. This is a task that would have taken at least 10 years to achieve, and we will now achieve it in 5 years. The cancer “moon landing plan” advocated by former US President Barack Obama in 2016 is also the focus of this summit. The plan is led by former Vice President Joe Biden. The goal is to break the boundaries that hinder the cooperation of researchers and accelerate the research of cancer diagnosis and treatment in the future. 5 years to double the progress of anti-cancer research. The six major US cancer “moon landing programs” include cancer vaccines, high-sensitivity cancer early detection, immunotherapy and combination therapy, single-cell genomic analysis of cancer cells and tumor microenvironment cells, new treatments for childhood cancer, and enhanced data. shared. To this end, the United States and Canada, Hong Kong, Germany, Switzerland, Japan, South Korea and other countries, the first-class research units to establish cooperative relations, large-scale joint cancer research and treatment, toward precision Medisun. The Medisun Medical Group is a member of the Cancer Month Program and will also participate in this historic mission. 
Mr. Terry Lierman talks about McGrady’s participation in the White House Cancer Month Plan
Medisun introduces Mayo proton beam therapy
Dr. Michael Haddock said: “The Mayo proton beam is a great advancement in the precise treatment of cancer!”
As the Asian Medical Service Center of the Mayo Clinic in the United States, Medisun invited Dr. Michael Haddock, Chairman of the Mayo Radiation Oncology Clinical Practice Committee and Vice Chairman of the American Society of Surgery Oncology (ACOSOG) Committee to talk about radiotherapy for cancer. Dr. Haddock talked about the current Proton Bean, the world’s leading cancer radiotherapy technology, Mayo currently has the most authoritative equipment, operations and medical team for global proton beam therapy. Mayo’s proton beam therapy program is the exclusive feature of pen beam scanning. It can accurately target tumors and prevent healthy tissues from being affected, thus achieving ideal cancer treatment, especially for treating children with cancer. For cancers with high mortality and lung cancer, proton beam therapy has obvious advantages compared with traditional radiotherapy.
At the Hong Kong Summit, Dr. Michael Haddock (left), the authoritative doctor of Mayo cancer proton beam therapy, answered questions from guests at the scene. 
Dr. Michael Haddock (left) and Mr. Terry Lierman (right), the authoritative doctors of Mayo cancer proton beam therapy, at the Guangzhou Summit.
Japanese NKT immune cell therapy
Dr. Degang said: “Cancer vaccine and NKT immune cell therapy are the strongest partner in cancer prevention and treatment!”
Haruhiro Tokuoka, CEO of Riken Immunization and Reproductive Medisun, Japan, Dr. Degang Governing, talked about immunotherapy for cancer. Japan has always been a pioneer in cancer immunotherapy and has extensive clinical experience. Japan Riken and Medisun have worked closely together and established the Medisun Precision Medical Joint Venture, which applies NKT immunocytotherapy outside the traditional cancer treatment to clinical treatment of various types of cancer in the early, middle and late stages, and has clinically proven to greatly improve cancer patients. High quality of immunotherapy at the same time as quality of life with almost no side effects.
Dr. Kazuoka Kazuo of Japan at the Hong Kong Summit to explain the effectiveness of NKT immune cell therapy in clinical treatment of cancer. 
Dean He Jianxing (second from right) of Guangzhou Medical First Hospital visited the Guangzhou Summit and participated in Dr. Degang Zhiwei (third from left) on cell immunotherapy
Precision Medisun and anti-cancer cancer
Ms. Yanglan said: “As a mother, I chose to give my daughter a HPV cervical cancer vaccine; now the launch of the cancer vaccine is even more exciting!”
In today’s society, everyone is tired of work, and it is often the easiest to ignore their good habits, which leads to the emergence of various diseases . In fact, “health is the first wealth of life”, Emerson’s famous interpretation perfectly interpreted the importance of a healthy life to people. Ms. Yang Lan, a well-known Chinese media person, attended the summit as a guest and shared ideas about health and happiness with the guests. She said that the pain caused by cancer patients to the family cannot be expressed in words, and health is good for every family. Precious, we need to follow the development of science and technology to update our medical knowledge. Nowadays, precision Medisun has brought us new choices. While we are not blindly following, we should fully understand the physical condition of ourselves and our families, and choose the right medical health program for ourselves. 
Ms. Yang Yu shared about cancer treatment. 
Ms. Wu Shuqing, the Honorary Director of the World Trade Center Association and the Standing Committee of the National Committee of the Chinese People’s Political Consultative Conference, was unable to visit the summit due to the temporary overseas meeting. She also sent a congratulatory message to the summit and congratulated Chairman Danny Wong of the Medisun Medical Group: “The summit has deepened Hong Kong with the Chinese mainland again, we are highly concerned about the medical and health industry. Therefore, I believe that Medisun Medical Group will continue its leading position in the field of medical and health care. Since the beginning, I have seen the entire team of Medisun under the leadership of Chairman Danny Wong. Unremitting efforts and dedication, I am convinced that today’s event is only the beginning, I hope that more results will be shared with the whole society.”
As a pioneer in the field of stem cells, cancer prevention and treatment in the world of regenerative , Medisun Medical Group has been committed to introducing the world’s leading cancer prevention and treatment technologies and providing the most advanced, professional and excellent medical and health services to the society. The release of the cancer vaccine is a revolutionary advancement in the field of cancer prevention. Ancient smallpox is terminally ill, and now a single shot of smallpox disappears; in the past, hepatitis B was terminally ill, and now a vaccine is immunized for life; yesterday, cancer is terminally ill, and today’s cancer vaccine keeps cancer away. Time is advancing and science is progressing. We must have a mentality of accepting progress. We believe that cancer prevention can provide shelter for the family and the health and well-being of society. 
Stay tuned: Hong Kong’s latest publication “CAPITAL” magazine in September, cover story “Mr. Danny Wong, Chairman of Medisun Medical Group” and cover story “New Revolution in Medical Industry”.
You can contact the Hong Kong Medisun Regenerative Medical Center to receive a magazine. Contact as below:
Phone: +(852) 2582 0188
Email: info@medisun.hk
WeChat: medisuninfo
Website: www.medisun.hk
****************************************
Medisun Medical Group
Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative products, as well as top hospitals and treatment centers. Located on the 25th floor of Ao Teng Plaza, Kowloon Bay, Hong Kong, the Medisun Reproductive Centre has a 50,000-square-foot stem cell GMP production facility, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to be rigorous and professional. The development process provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. More than 3,000 biomedical tests provide the most predictable health protection for the health of our clients. Medisun has been fully supporting the development of the new life and health platform, and is committed to the deepening of the new products and technologies of regenerative Medisun through this platform, truly benefiting the health of the whole society.
For more details, please visit http://www.medisun.hk/
Cryolife tech news
Asian’s Godfather of Cord Blood, Professor Takahashi Tsuneo Joined the “Cryolife Cord Blood Bank” and “Hong Kong Medisun”
In May 2017, CRYOLIFE Cord Blood Bank (Hong Kong Medisun Medical Group members) formally appointed the Godfather of Cord Blood in Asia, Japanese regenerative medicine expert Professor Takahashi Tsuneo as the Chief Scientist. Professor Takahashi will lead all the cord blood stem cell research projects. Professor Takahashi has eras of experience in the field of regenerative medicine. In the past few decades, Professor Takahashi has established the standards of the Cryo-Cord Blood in Asia and lead a new prospective in the application and development of the cord blood industry.
It is well believes that by the joining of Professor Takahashi will convey a new development stage in the field of cord blood stem cells in Hong Kong. It will bring new opportunities for the expansion of Medisun Medical Group and the Cryolife Cord Blood Bank.
Professor Takahashi Tsuneo is committed to the field of regenerative medicine for more than 40 years (mainly in the field of stem cells and cord blood bank). Currently he serves as Chief Executive Officer of Japan LIFEBANK and Chief Scientist of Hong Kong Cryolife Cord Blood Bank (Cryolife is a members of the Medisun Group). Prof. Takashi Tsuneo graduated from the Hokkaido University in Sapporo, Japan with a Ph.D. degree. He became the scientist in the Red Cross of Bethesda, Maryland. He later worked at the Research center for Arthritis, Diabetes and Kidney diseases of the National Institutes of Health in Bethesda, Maryland. Professor Takahashi Tsuneo returned to Japan, became the Red Cross Hokkaido Blood Center’s Research Director in Sapporo. Professor Takahashi is not only a founding member of the International Cord Blood Bank Alliance (NETCORD), but also Director of the Tokyo Cord Blood Bank Cell Treatment Center at the University of Tokyo, Japan, and Director of Cellular Research and Development for research center for cell therapy in New York. Professor Takahashi is a Visiting Professor at a number of well-known institutions, including: Department of Cellular Processing, Institute of Medical Sciences, University of Tokyo, Head of Hematology, Tokyo University Hospital, Head of Embryonic Stem Cell Research, Faculty of Forensic Medicine, Kyoto University, Kobe University Institute of Medicine and Pathology, and Department of Medicine, Peking University, China.
Application of Cord Blood
Cord blood is originated in the fetus, and collected at the umbilical cord ligation when separated from the residual placenta. Nearly a decade of research and discovered that umbilical cord blood contain the human hematopoietic and the hematopoietic stem cells of the immune system. It can be used for hematopoietic stem cell transplantation, for the treatment of more than 80 kinds of diseases. Thus, the cord blood has become an important source of hematopoietic stem cells, especially for no directly related family members. The hematopoietic stem cells is a very important human biological for treatment of diseases.
Worldwide, cord blood has been used to treat various types of Leukemia, Aplastic Anemia, Lymphoma, Multiple Myeloma, Neuroblastoma, Mucopolysaccharide disease, Thalassemia, Bone Marrow Dysplasia syndrome, Primary Immunodeficiency Disease, Chronic Granuloma and other 80 kinds of diseases.
Clinical application case
* The world’s first cord blood transplantation: In 1988, a 5-year-old French boy, suffering from Cooley’s Anemia has been treated with the cord blood transplantation and with completely recovered.
* The world’s first autologous cord blood transplantation: In 1997, a 14-month-old Brazilian girl, with autologous cord blood successfully cured Neuroblastoma.
* The world’s first double dosages of cord blood transplantation: In 2000, the Institute of Hematology of the Peking University used the world’s first double dose of cord blood transplantation for the treatment of Acute Lymphoblastic Leukemia with good result. Now, the patient weight of 95 kg, is having a healthy life.
* Asia’s first autologous cord blood transplantation: In 2009, Beijing Children’s Hospital, a pediatric patient using his own cord blood for the treatment of Neuroblastoma. This is the first case of autologous cord blood treatment for pediatric case. The baby is treated and being fine after the transplantation.
* China treated a youngest and light weight baby: In 2009, Shanghai Dao Pei Hospital has successfully treated a 2 months old baby only weight – 5 kg, by using the cord blood transplantation treatment for Primary Immunodeficiency Disease.
* In China, the first mother received the son’s cord blood transplantation as treatment: In 2009, Chongqing Xinqiao Hospital, a female patient suffering from an Acute Non-Lymphocytic Leukemia was treated by using her son’s umbilical cord blood, together with his husband’s bone marrow for transplantation. She was discharged from the Intensive Care Unit after one month from the transplantation. This is the first case of mother using her child’s cord blood for transplantation.
Treatment prospects
Cell therapy has been a biological way for the treatment of a number of diseases in the 21st century. At the end of May 2014, the worldwide of related clinical research on the cord blood cell therapy, registered with the United States National Institutes of Health (NIH) reached a total of 928.
CRYOLIFE Cord Blood Bank – Hong Kong’s first private cord blood bank
CRYOLIFE Cord Blood Bank is the only one in Hong Kong with the most international professional certification, and is highly recommended by gynecologist, physicians and parents. CRYOLIFE was established in 1996 to create the first private cord blood storage program in Asia. Prior to the establishment of the cord blood bank in Japan, Singapore, mainland China, Taiwan and Malaysia. Cryolife upgrades the standards in the development and research in the laboratory equipment. It is the leader in Hong Kong and Asian in the cord blood industry. CRYOLIFE has been recognized by the American Association of Blood Banks (AABB) since 2007 as one of the world’s first recognized AABB-approved cord blood banks, and range the first 50 in the Cord Blood Bank’s list. Continuous assessment were done in 2009, 2011, 2013 and 2015 and has successfully passed the review, and gain the AABB certification until the end of 2017. The company is the only one in Hong Kong which has obtained a 10 consecutive years’ certification in the private cord blood bank. (In February 2017) Hong Kong Medisun Medical Group acquired 51% stake in CRYOLIFE Cord Blood Bank as its controlling shareholder.)
MEDISUN MEDICAL GROUP
Headquartered in Hong Kong, Headquartered in Hong Kong, the company is committed to investing in R & D and commercialization of global regenerative medicine products, as well as professional medical investment groups in top hospitals and treatment centers.
Medisun invests extensively in regenerative medicine and stem cell patented technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, neurological diseases, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical and the US Mayo Clinic, Harvard University Stem Cell Research Institute, Johns Hopkins School of Life Science Center launched a long-term cooperation program, co-investment in regenerative medicine and stem cell therapy technology. Medisun collaborates with them as the business owned holdings and holds global intellectual property rights.
The Medisun Regenerative Medical Center is located in Kowloon, Hong Kong , with 50,000 square feet of stem cell GMP production base, cancer treatment center and anti-aging center, bringing together European, Japanese, American and individual Chinese experts for rigorous professional development process by providing immune cell therapy and a variety of stem cell treatments. Medisun is also the Asian Center, a representative of the Mayo Clinic Asia service agencies. It provides Mayo remote consultation, the second diagnosis and treatment, so that Chinese patients can not enjoy the authority of the medical services. Mayo Clinic provides more than three thousand biomedical tests for the most predictable health protection for our customers’ health.
Medisun Regenerative Medicine Center (Mayo Asia Medical Service Center | Cancer Treatment Center | Anti-Aging Center)
Medisun Medical Laboratory (Hong Kong)
Source : http://www.medisun.hk/
PT. Kamadjaja Logistics
PT. Kamadjaja Logistics was recently named Frost & Sullivan’s 2017 Indonesia Domestic Warehouse Services Provider of the Year at the annual Frost & Sullivan Indonesia Excellence Awards ceremony, held at the Mandarin Oriental Hotel, Jakarta on 28 November 2017.
“Recognizing the importance of innovation and meeting customer needs, PT. Kamadjaja Logistics has focused on developing and improving its warehousing infrastructure and technologies. The company’s cutting edge warehousing facilities such as its successful KLOG PARK establishments have enabled customers to derive maximum value from top-notch services, allowing the company to enjoy a better relationship with customers,” said Norazah Bachok, Research Analyst for Transportation & Logistics at Frost & Sullivan.
She continued, “PT. Kamadjaja Logistics also aims for more partnerships with various regional participants to boost opportunities. An extensive product portfolio, new business chain ventures, regional partnerships, and expansion strategies allow the company to enhance its brand recognition and value in the industry.”
“We are delighted to receive the 2017 Indonesia Domestic Warehouse Services Provider of the Year award from Frost & Sullivan. This recognition is a huge encouragement to the team as we strive to provide value to our customers by delivering innovative and excellent logistics services,” said Ivy Kamadjaja, Deputy CEO of PT. Kamadjaja Logistics.
The recipients of the annual Frost & Sullivan Indonesia Excellence Awards were identified based on in-depth research conducted by Frost & Sullivan’s analysts. The award categories offered each year are carefully reviewed and evaluated to reflect the current market landscape and include new emerging trends.
The short-listed companies were then evaluated on a variety of actual market performance indicators which include revenue growth; market share and growth in market share; leadership in product innovation; marketing strategy and business development strategy.
About PT. Kamadjaja Logistics
PT. Kamadjaja Logistics is widely recognized as a pioneer in the logistics industry in Indonesia. Established five decades ago it is now the largest Indonesian company that provides integrated and modern logistics solutions. Equipped with 29 Distribution Centers spread over 16 major cities in Indonesia and covering over 355 destinations, PT. Kamadjaja Logistics has the largest nationwide logistics network in the country.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion
Contact:
Fuad Misbah
Corporate Communications – Indonesia
Email: fuad.misbah@frost.com
http://www.frost.com
The Mary C. O’Keefe Cultural Center Will Host Hurricane Harvey Benefit Show September 24th
Who knew a devastating hurricane in the Texas Gulf Coast would inspire so many communities across America to pitch-in and help? But that’s exactly what’s happening September 24th in Ocean Springs, Mississippi when “FRANK & LIZA” come to the Mary C. This strong community already knows the impact of a record-breaking storm. In 2005, Hurricane Katrina ravaged their own coastline. But today, it’s Houston and the Texas coast that urgently need the help.
Thanks to the Mary C. O’Keefe Cultural Center, the exhilarating musical tribute to “Frank Sinatra & Liza Minnelli” will come to Ocean Springs for one Sunday matinee benefiting the Hurricane Harvey Relief Fund. The show is a rapid-paced musical journey through the classic and timeless hits of Frank Sinatra and the Broadway-like song and dance spectacle that is Liza Minnelli’s trademark.
Described as “warm, witty and sexy”, the Las Vegas show features a delightful exchange of music, humor and dazzling duets between two of the most talented artists working today – Dave Halston and Suzanne Goulet. Together, “FRANK & LIZA” will not only thrill a willing audience, they will make it easy for virtually anyone to assist in the Hurricane Harvey relief effort.
Seating is limited. Tickets are available online now for $25.
About the Hurricane Harvey Relief Fund:
After receiving an overwhelming number of inquiries from citizens and companies who want to help, Houston Mayor Sylvester Turner and County Judge Ed Emmett have established the Hurricane Harvey Relief Fund that will accept tax deductible flood relief donations for victims that have been affected by the recent floods. The fund will be housed at the Greater Houston Community Foundation, a 501(c)(3) public charity.
About the Artists:
Dave Halston comes with an impressive resume – working a multitude of theatres, casinos, special events and private parties coast to coast – and in most cases, leaving the audience stunned. As one observer described it, “Dave Halston somehow casts a spell, and they always want more.” Even Barbara Sinatra was brought to tears when Dave performed for her at an exclusive private event. She called his performance “wonderful” and noted specifically the fine job Dave did with Sinatra’s signature song “My Way”.
In addition to Mrs. Sinatra, Dave has also entertained Jeanne Martin (Mrs. Dean Martin), recording artists Michael Feinstein, Steve Tyrell and Mr. Las Vegas himself, Wayne Newton, among other notables.
Suzanne Goulet was born in Montreal, Canada and has been dancing since the age of 3. She starred in “Fantastique” at the Sheraton Bal Harbour in Miami Beach, then at the Sands Casino in Atlantic City and at the Condado Plaza in San Juan, Puerto Rico. She then joined “Hooray for Hollywood” for an international tour to Spain, Switzerland and Japan. She also choreographed and danced for a show on the “Song of America” cruise ship from RCCL. After studying voice in New York City, she won the “Smirnoff Makes You A Star” competition and began her career as a tribute artist.
In 1996, Suzanne joined “Legends in Concert” at Bally’s Grand in Atlantic City. Then she followed the show to the Imperial Palace in Las Vegas where she received rave reviews and numerous awards.
Show Details:
“FRANK & LIZA”
A Musical Tribute to Frank Sinatra and Liza Minnelli
2:30PM | Sunday, September 24th, 2017
TICKETS: $25
The Mary C. O’Keefe Cultural Center of Arts and Education
1600 Government Street
Ocean Springs, Mississippi 39564
228.818.2878
Harvard University Stem Cell Institute and Hong Kong National Investment starting a strong cooperation
Hong Kong National Investment and Harvard University Stem Cell Institute have a strong cooperation.
Mr. Brock Reeve, CEO of Harvard Stem Cell Research Institute, is the Chief Investment Officer of Stem Cell and Regenerative Medisun at National Investment and Medici Medical Group.
2015-05-11 China Securities Journal
On May 8, 2015, Hong Kong Medisun Regerative Medical Center and National Investment (01227.HK) announced the appointment of Mr. Brock Reeve as the chief stem cell and regenerative medicine investment officer of the two companies.
Mr. Brock Reeve is currently the Executive Director of the Harvard University Stem Cell Institute and has graduated from Yale University and Harvard Business School. Mr. Reeve is solely responsible for the strategy and operations of the Harvard Stem Cell Institute, whose overall goal is to use stem cell biology as a tool and treatment to study and treat major degenerative diseases.
As the Chief Investor of Stem Cell and Regenerative Medicine of Medisun Medical Center, Mr. Brock Reeve will organize and lead a professional investment team to actively select the latest regenerative medicine technologies in overseas markets such as Europe, the United States, and Japan and evaluate their investment value. They will also focus on and invest in the world’s leading stem cell regenerative medicine technology, and actively participate in clinical trials and product commercialization of stem cell technology invested by Medisun Medical Center in Asia.
Medisun Medical Center is the world’s most authoritative investment organization in stem cell and regenerative medicine
As the world’s most authoritative investment organization for stem cells and regenerative medicine, Medisun Medical Center has invested in stem cell treatment technologies including heart, tumor, liver, kidney, AIDS and other diseases, fully demonstrating its investment vision and courage. After working with the Mayo Medical Group in the United States, the Medisun once again joined forces with the Harvard University Stem Cell Institute.
Mr. Danny Wong is both the Chairman of the Medisun Medical Group and National Investment (01227.HK). He has devoted himself to research and investment in the field of stem cells for the past five years. The Medisun currently has more than 300 scientists , medical consultants and investment experts from all over the world. The technologies invested by the group are distributed in Europe, the United States, Japan, Hong Kong and other places, and clinical trials are carried out simultaneously.
China’s first participation in international multi-center global synchronized clinical trials
Medisun Medical Group is committed to bringing the world’s leading stem cell and regenerative medicine technologies to China. The investment in the C-cure stem cell therapy for ischemic heart failure technology, which was invented by Mayo Medical Group, has been clinically tested in Europe and the United States. It will carry out clinical trials in China’s well-known cardiovascular hospitals such as Beijing Anzhen Hospital, Fuwai Cardiovascular Hospital and Shanghai Oriental Hospital with the support of international multi-center policy, giving Chinese hospitals the opportunity to participate in the world’s most advanced stem cell technology clinic. The Medisun also actively promote the commercialization of technology worldwide in the future. Before C-Cure’s great technology and revolutionary products for heart disease were officially launched, Medisun has launched a series of cell regeneration factor products to treat a number of diseases, and the product has entered the market.
Liang Zhen ying visits Harvard University Stem Cell Research Institute and Mr. Brock Reeve to discuss the promotion of stem cell and the development of regenerative medicine industry
Under the general environment of Hong Kong’s adjustment of the whole industry, one of the important measures is to develop the stem cell and regenerative medicine industries. Looking at the huge investment in the stem cell and regeneration field of the Medisun Medical Group, it is revealed that it will inevitably set off a disruptive business model in the market.
The Hong Kong government attaches great importance to the development of stem cells. Following the cooperation with the Caroline Medical School in Sweden, Liang Zhen ying visited the Harvard University Stem Cell Research Institute on May 5 and exchanged views with its Executive Director Brock Reeve to promote the development of the stem cell industry in Hong Kong. This will undoubtedly inject a strong shot into the cooperation between Harvard University and Hong Kong in the field of regenerative medicine. It will promote the promotion of Harvard stem cells in regenerative medicine research and technology in Hong Kong and Asia.
It can be seen that Medisun Medical Group has appointed Mr. Brock Reeve take the helm of the stem cell and regenerative medicine to investment. National Investment (01227.HK), which holds a 30% stake in Medisun Medical Group, is investing in regenerative medicine and the field of stem cells. Mr. Brock Reeve will lead the Medisun Medical Group to become a professional stem cell investment team with global leadership.
The value of the stem cell and regenerative medicine industry under the capital market in China and Hong Kong is immeasurable.
With the upcoming clinical management of stem cells, the development of China’s stem cell and regenerative medicine industry will be unstoppable. Shanghai-Hong Kong Stock Connect and the upcoming Shenzhen-Hong Kong Stock Connect have apparently injected huge sums of money into Hong Kong stocks. The stocks of companies related to the stem cell industry have risen very well, but they are far from satisfactory and far from the technology held by Medisun Medical Center. National Investment (01227.HK), as a shareholder of Medisun Medical Group, is full of confidence in the development of the Group.
Medisun Investment Holdings’ Cardio Biotech plans to enter the US capital market.
Medisun Investment Holdings’ C-cure Stem Cell Therapy for Ischemic Heart Failure has exceeded the number of patients enrolled by the European Food and Drug Administration (EMA) in the Phase III clinical trial in Europe and has been approved by the US Food and Drug Administration (FDA). Enter the third phase of clinical. Cardio, the investment holding company of Medisun, also successfully obtained a new round of financing of 32 million euros in February this year. Its financing quota was oversubscribed and snapped up by European and American institutional investors. Cardio is planning to be listed on the NASDAQ in the United States from the end of May to the beginning of June this year (listed in Belgium and France in 2013), and the large-scale financing plan of Cardio further indicates that the spring of stem cells has really come.
After many years of favor and investment in the field of stem cells and regenerative medicine, and the huge capital investment plan, the Medisun’ next step will be the focus of the market. The capital market’s confidence in its shareholder, National Investment (01227.HK), is already evident in the expectation of its future development.According to analysts, Medisun has planned to launch an overall listing financing plan in Hong Kong in the near future. We believe that Medisun, as a recognized leader in the global stem cell and regenerative medicine field, will surely launch an incredible wave of development in this field.
The News Picture:
P1:
Mr. Brock Reeve is both the chairman of Medisun medical group and National Investment (01227.HK) and a close friend of Mr. Danny Wong during his stay in the United States.They share the same confidence and enthusiasm for stem cell and regenerative medicine.
P2:
Hong Kong Chief Executive Liang Zhen ying visited the Harvard University Stem Cell Institute and exchanged views with the Executive Director, Mr. Brock Reeve, on the development of the stem cell and regenerative medicine industries.
Source: http://www.medisun.hk/
Brock Reeve is the younger brother of the famous American actor Christopher Reeve. Christopher Reeve (September 25, 1952 – October 10, 2004), a New Yorker, famous movie actor, film director, writer, was play in Superman (Kal-El/Clark Kent). He graduated from Cornell University in 1974 with a Bachelor of Arts degree and then entered the Juilliard School in New York. He is also a good friend with another famous actor Robin Williams. In 1978, he starred in the sci-fi film “Superman” for the first time and became a hit. In 1995, an accident occurred during an equestrian competition. The spine was seriously injured and his body was paralyzed. Since then, he has devoted himself to social welfare undertakings and to promote stem cell research. He often holds tour lectures. On October 9, 2004, he died for the myocardial infarction at the age of 52.
